AstraZeneca to acquire vaccine developer Icosavax in deal worth up to $1.1bn

12 Dec 2023
·
Deals
www.pmlive.com
VaccineLicense out/inAcquisitionPhase 3
AstraZeneca (AZ) has announced that it will be acquiring Icosavax in a deal worth up to $1.1bn, strengthening the Anglo-Swedish drugmaker’s late-stage vaccine pipeline.
AstraZeneca (AZ) focuses on developing vaccines against iIcosavaxs diseases using its protein virus-like particle (VLP) platform.
As VLP vaccines mimic how naturally occurring viruses apinfectious diseasesimmune system, they could offer benefits over non-VLP vaccines, including a stronger immune response, greater breadth of protection and increased durability.
Icosavax’s lead candidate is a phase 3-ready combination protein VLP vaccine targeting both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), two leading causes of severe respiratory infection and hospitalisation in older adults and people with chronic conditions.
The asset, IVX-A12, has a differentiated profile versus currently approved RSV vaccines, according to AZ, and has already been shown in a mid-stage study to elicit robust immune responses arespiratory infectionMPV one month after vaccination.
Iskra Reic,IVX-A12ive vice president, vaccines and immune therapies, AZ, saRSV vaccinesP vaccine technology has the potential to transform prevention against severe infectious diseases, including RSV and hMPV.
"With the addition of Icosavax’s phase 3-ready lead asset to our late-stage pipeline, we will have a differentiated, advanced investigational vaccine and a platform infectious diseasesment of combination vaccines against respiratory viruses.”
Under the terms of theIcosavaxnt, AZ will initiate a tender offer to acquire all of Icosavax’s outstanding shares for a price of $15 per share in cash at closing, plus a non-tradable contingent value right for up to $5 per share in cash payable upon achievement of a specified regulatory milestone and a sales milestone.
Adam Simpson, chief executive offiAZr, Icosavax, said: "We look forward to combiningIcosavaxlls and expertise in advancing the development of IVX-A12 with AZ’s decades of experience in RSV, resources and capabilities in late-stage development.”
The acquisition is just one of a seriesIcosavaxs that AZ has made this year. Earlier this month, it entered into a collaboration agreement worIVX-A12o $247AZwith Absci to develop an artRSVcial intelligence-designed antibody drug for a specified oncology target.
The company also entered into an exclusive licence agrAZment worth almost $420m with Chinese biotech Usynova last month for global rights to preclinical small molAbsci drug candidate UA022.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.